Cargando…

Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools

Zika virus (ZIKV), an emerging arthropod-borne virus (arbovirus) of the Flaviviridae family, is a current issue worldwide, particularly because of the congenital and neurological syndromes associated with infection by this virus. As the initial clinical symptoms of all diseases caused by this group...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Isaura Beatriz Borges, da Silva, Aldacilene Souza, Cunha, Mariana Sequetin, Cabral, Aline Diniz, de Oliveira, Kelly Cristina Alves, Gaspari, Elizabeth De, Prudencio, Carlos Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Estudos de Venenos e Animais Peçonhentos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685096/
https://www.ncbi.nlm.nih.gov/pubmed/33281886
http://dx.doi.org/10.1590/1678-9199-JVATITD-2020-0019
_version_ 1783613124415324160
author Silva, Isaura Beatriz Borges
da Silva, Aldacilene Souza
Cunha, Mariana Sequetin
Cabral, Aline Diniz
de Oliveira, Kelly Cristina Alves
Gaspari, Elizabeth De
Prudencio, Carlos Roberto
author_facet Silva, Isaura Beatriz Borges
da Silva, Aldacilene Souza
Cunha, Mariana Sequetin
Cabral, Aline Diniz
de Oliveira, Kelly Cristina Alves
Gaspari, Elizabeth De
Prudencio, Carlos Roberto
author_sort Silva, Isaura Beatriz Borges
collection PubMed
description Zika virus (ZIKV), an emerging arthropod-borne virus (arbovirus) of the Flaviviridae family, is a current issue worldwide, particularly because of the congenital and neurological syndromes associated with infection by this virus. As the initial clinical symptoms of all diseases caused by this group are very similar, clinical diagnosis is difficult. Furthermore, laboratory diagnostic efforts have failed to identify specific and accurate tests for each virus of the Flaviviridae family due to the cross-reactivity of these viruses in serum samples. This situation has resulted in underreporting of the diseases caused by flaviviruses. However, many companies developed commercial diagnostic tests after the recent ZIKV outbreak. Moreover, health regulatory agencies have approved different commercial tests to extend the monitoring of ZIKV infections. Considering that a specific and sensitive diagnostic method for estimating risk and evaluating ZIKV propagation is still needed, this review aims to provide an update of the main commercially approved serological diagnostics test by the US Food and Drug Administration (FDA) and Brazilian National Health Surveillance Agency (ANVISA). Additionally, we present the technologies used for monoclonal antibody production as a tool for the development of diagnostic tests and applications of these antibodies in detecting ZIKV infections worldwide.
format Online
Article
Text
id pubmed-7685096
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Centro de Estudos de Venenos e Animais Peçonhentos
record_format MEDLINE/PubMed
spelling pubmed-76850962020-12-03 Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools Silva, Isaura Beatriz Borges da Silva, Aldacilene Souza Cunha, Mariana Sequetin Cabral, Aline Diniz de Oliveira, Kelly Cristina Alves Gaspari, Elizabeth De Prudencio, Carlos Roberto J Venom Anim Toxins Incl Trop Dis Review Zika virus (ZIKV), an emerging arthropod-borne virus (arbovirus) of the Flaviviridae family, is a current issue worldwide, particularly because of the congenital and neurological syndromes associated with infection by this virus. As the initial clinical symptoms of all diseases caused by this group are very similar, clinical diagnosis is difficult. Furthermore, laboratory diagnostic efforts have failed to identify specific and accurate tests for each virus of the Flaviviridae family due to the cross-reactivity of these viruses in serum samples. This situation has resulted in underreporting of the diseases caused by flaviviruses. However, many companies developed commercial diagnostic tests after the recent ZIKV outbreak. Moreover, health regulatory agencies have approved different commercial tests to extend the monitoring of ZIKV infections. Considering that a specific and sensitive diagnostic method for estimating risk and evaluating ZIKV propagation is still needed, this review aims to provide an update of the main commercially approved serological diagnostics test by the US Food and Drug Administration (FDA) and Brazilian National Health Surveillance Agency (ANVISA). Additionally, we present the technologies used for monoclonal antibody production as a tool for the development of diagnostic tests and applications of these antibodies in detecting ZIKV infections worldwide. Centro de Estudos de Venenos e Animais Peçonhentos 2020-11-18 /pmc/articles/PMC7685096/ /pubmed/33281886 http://dx.doi.org/10.1590/1678-9199-JVATITD-2020-0019 Text en https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Review
Silva, Isaura Beatriz Borges
da Silva, Aldacilene Souza
Cunha, Mariana Sequetin
Cabral, Aline Diniz
de Oliveira, Kelly Cristina Alves
Gaspari, Elizabeth De
Prudencio, Carlos Roberto
Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools
title Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools
title_full Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools
title_fullStr Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools
title_full_unstemmed Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools
title_short Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools
title_sort zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685096/
https://www.ncbi.nlm.nih.gov/pubmed/33281886
http://dx.doi.org/10.1590/1678-9199-JVATITD-2020-0019
work_keys_str_mv AT silvaisaurabeatrizborges zikavirusserologicaldiagnosiscommercialtestsandmonoclonalantibodiesastools
AT dasilvaaldacilenesouza zikavirusserologicaldiagnosiscommercialtestsandmonoclonalantibodiesastools
AT cunhamarianasequetin zikavirusserologicaldiagnosiscommercialtestsandmonoclonalantibodiesastools
AT cabralalinediniz zikavirusserologicaldiagnosiscommercialtestsandmonoclonalantibodiesastools
AT deoliveirakellycristinaalves zikavirusserologicaldiagnosiscommercialtestsandmonoclonalantibodiesastools
AT gasparielizabethde zikavirusserologicaldiagnosiscommercialtestsandmonoclonalantibodiesastools
AT prudenciocarlosroberto zikavirusserologicaldiagnosiscommercialtestsandmonoclonalantibodiesastools